Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis (ILIT-T)
The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen
Sponsor: Gachon University Gil Medical Center
Listed as NCT02665754, this PHASE1 trial focuses on Allergic Rhinitis and remains completed. Sponsored by Gachon University Gil Medical Center, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gachon University Gil Medical Center
- Korea Research Foundation
For direct contact, visit the study record on ClinicalTrials.gov .